Therapeutical aspects of using citalopram in burns.
CONCLUSION OF THE ICU: Preliminary results from this stage of our study demonstrate a significant decrease of the duration of oedema, probably due to the effects of the inhibition of vascular hyperpermeability. This means that patients under Citalopram therapy can undergo surgical procedures such as necrectomies and autografts sooner because they are stabilized as early as the beginning of their treatment. Particularly the patients with burned faces and deep dermal burns have a better prognoses in respect to cosmetics. CONCLUSION OF THE PSYCHOLOGIST: From the beginning of the study to the present time, no patient experienced PTSD. The compared group of out-patients had been treated on average of 3 months when the first signs of a reduction in the clinical symptoms of PTSD was registered. The clinical onset of the therapeutical effect--on average in the third week--is comparable with references from anxiety or inhibitory depression treatment by using Citalopram. We suggest, at present, that the above-mentioned, preliminary results of our study have shown that Citalopram treatment has a beneficial effect on emotional disturbances in severely burned patients. CONCLUSION OF THE SCAR SPECIALIST: Seropram is a very useful preparation in burn praxis. When we apply it as a bolus 40 mg i.v. immediately after admission to the ICU, the scarring process is very good and hypertrophic scars are not seen. When we apply Seropram in the form of a continual infusion, using the injectomat during a 24-hour period, scarring is better than in the control group, but hypertrophic scarring is not out of the question.
Klinika popáleninové medicíny FNKV Praha.
J
J
Bláha
K
K
Svobodová
Z
Z
Kapounková
D000293:Adolescent; D000328:Adult; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control* / Q000523:psychology; D015283:Citalopram / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013312:Stress, Physiological / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D016896:Treatment Outcome
D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors